JP2005512518A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512518A5
JP2005512518A5 JP2003532534A JP2003532534A JP2005512518A5 JP 2005512518 A5 JP2005512518 A5 JP 2005512518A5 JP 2003532534 A JP2003532534 A JP 2003532534A JP 2003532534 A JP2003532534 A JP 2003532534A JP 2005512518 A5 JP2005512518 A5 JP 2005512518A5
Authority
JP
Japan
Prior art keywords
heat shock
shock protein
protein fragment
fragment
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003532534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512518A (ja
Filing date
Publication date
Priority claimed from GBGB0123756.9A external-priority patent/GB0123756D0/en
Application filed filed Critical
Publication of JP2005512518A publication Critical patent/JP2005512518A/ja
Publication of JP2005512518A5 publication Critical patent/JP2005512518A5/ja
Withdrawn legal-status Critical Current

Links

JP2003532534A 2001-10-03 2002-10-03 熱ショックタンパク質の使用 Withdrawn JP2005512518A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0123756.9A GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1
PCT/GB2002/004475 WO2003029289A2 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Publications (2)

Publication Number Publication Date
JP2005512518A JP2005512518A (ja) 2005-05-12
JP2005512518A5 true JP2005512518A5 (enExample) 2006-02-02

Family

ID=9923176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003532534A Withdrawn JP2005512518A (ja) 2001-10-03 2002-10-03 熱ショックタンパク質の使用

Country Status (7)

Country Link
US (1) US20060264609A1 (enExample)
EP (1) EP1434794A2 (enExample)
JP (1) JP2005512518A (enExample)
AU (1) AU2002329450A1 (enExample)
CA (1) CA2463404A1 (enExample)
GB (1) GB0123756D0 (enExample)
WO (1) WO2003029289A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512173A (pt) * 2004-06-15 2008-02-12 New York Blood Ct Inc composição imunogênica, e, métodos para potenciar uma resposta imune especìfica a um antìgeno, para estimular uma resposta celular com secreção de citocinas, para gerar uma resposta imune em um mamìfero em necessidade do mesmo contra oncocerciase, e para prevenir sars, e hiv em um mamìfero em necessidade do mesmo
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
CN101801402B (zh) * 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防
ES2963910T3 (es) 2008-06-26 2024-04-03 Zevra Denmark As Uso de Hsp70 como regulador de la actividad enzimática
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
PT2646044T (pt) 2010-11-30 2019-11-12 Orphazyme As Métodos para aumentar a atividade intracelular de hsp70
HUE054957T2 (hu) 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
US20170260286A1 (en) * 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
RU2021117465A (ru) 2016-04-29 2021-07-22 Орфазим А/С Аримокломол для лечения ассоциированных с глюкоцереброзидазой нарушений
US11325951B2 (en) * 2016-09-09 2022-05-10 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of cancer
CN116322771A (zh) * 2020-10-09 2023-06-23 志瑞亚新药工业株式会社 结核杆菌提取物的新型用途
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777890B1 (fr) * 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
ATE392479T1 (de) * 1999-10-20 2008-05-15 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
AU2002242016A1 (en) * 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation

Similar Documents

Publication Publication Date Title
JP2008529558A5 (enExample)
TW510921B (en) Modified TNFα molecules, DNA encoding such modified TNFα molecules and vaccines comprising such modified TNFα molecules and DNA
JP2002542827A5 (enExample)
JP2005512518A5 (enExample)
JP2010500399A5 (enExample)
JP2006141398A5 (enExample)
JP2013507907A5 (enExample)
JP2008525033A5 (enExample)
JP2010516290A5 (enExample)
JP2004501618A5 (enExample)
JP2003500040A5 (enExample)
JP2005530716A5 (enExample)
CA2395499A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP2019506175A5 (enExample)
RU2006105498A (ru) Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
JP2025094154A5 (enExample)
CA2385325A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP2003530088A5 (enExample)
JP2019534884A5 (enExample)
JPWO2021116462A5 (enExample)
WO2022071513A1 (ja) SARS-CoV-2に対する改良型DNAワクチン
JPWO2018234492A5 (enExample)
JP2020509770A5 (enExample)
JP2010535504A5 (enExample)
RU2004134331A (ru) Антиген muc1 со сниженным числом повторяющихся vntr-блоков